XENETIC BIOSCIENCES INC (XBIO) Stock Price, Quote, News and Overview
NASDAQ:XBIO - Nasdaq - US9840156023 - Common Stock - Currency: USD
XBIO Quote, Performance and Key Statistics
NASDAQ:XBIO (5/13/2025, 4:00:14 PM)
3.06
-0.04 (-1.29%)
The current stock price of XBIO is 3.06 USD. In the past month the price increased by 26.97%. In the past year, price decreased by -15.19%.
XBIO Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.31 | 332.57B | ||
| AMGN | AMGEN INC | 13.03 | 145.41B | ||
| GILD | GILEAD SCIENCES INC | 13.1 | 126.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.06B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.96 | 61.99B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.71B | ||
| ARGX | ARGENX SE - ADR | 92.41 | 33.12B | ||
| ONC | BEIGENE LTD-ADR | 5.58 | 24.22B | ||
| BNTX | BIONTECH SE-ADR | N/A | 22.72B | ||
| NTRA | NATERA INC | N/A | 20.70B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 18.28B | ||
| BIIB | BIOGEN INC | 7.79 | 18.05B |
Related stock screener links
About XBIO
Company Profile
Xenetic Biosciences, Inc. is a biopharmaceutical company engaged in the advancement of cell-based therapeutics to target the B-cell receptor on the surface of an individual patient’s malignant tumor cells. The company is headquartered in Framingham, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2016-11-07. The firm is focused on advancing immuno-oncology technologies addressing difficult to treat cancers. The firm's Deoxyribonuclease (DNase) technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. The company is focused on advancing the development of its DNase technology toward a first-in-human, multicenter, dose escalation and dose-expansion study of IV rhDNase I in subjects with locally advanced or metastatic solid tumors. Its systemic DNase program is initially targeting multi-billion-dollar indications including pancreatic ductal adenocarcinoma (PDAC), colorectal carcinoma and other gastrointestinal cancers. These are all cancer indications with significant unmet need, and with opportunities for substantial improvement of the currently available therapeutic options.
Company Info
XENETIC BIOSCIENCES INC
945 Concord St.
Framingham MASSACHUSETTS 01701 US
CEO: Jeffrey F. Eisenberg
Employees: 2
Phone: 17817787720
XENETIC BIOSCIENCES INC / XBIO FAQ
What is the stock price of XENETIC BIOSCIENCES INC today?
The current stock price of XBIO is 3.06 USD. The price decreased by -1.29% in the last trading session.
What is the ticker symbol for XENETIC BIOSCIENCES INC stock?
The exchange symbol of XENETIC BIOSCIENCES INC is XBIO and it is listed on the Nasdaq exchange.
On which exchange is XBIO stock listed?
XBIO stock is listed on the Nasdaq exchange.
What is XENETIC BIOSCIENCES INC worth?
XENETIC BIOSCIENCES INC (XBIO) has a market capitalization of 4.71M USD. This makes XBIO a Nano Cap stock.
How many employees does XENETIC BIOSCIENCES INC have?
XENETIC BIOSCIENCES INC (XBIO) currently has 2 employees.
What are the support and resistance levels for XENETIC BIOSCIENCES INC (XBIO) stock?
XENETIC BIOSCIENCES INC (XBIO) has a support level at 3.05 and a resistance level at 3.07. Check the full technical report for a detailed analysis of XBIO support and resistance levels.
Is XENETIC BIOSCIENCES INC (XBIO) expected to grow?
The Revenue of XENETIC BIOSCIENCES INC (XBIO) is expected to grow by 27.27% in the next year. Check the estimates tab for more information on the XBIO EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy XENETIC BIOSCIENCES INC (XBIO) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of XBIO, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of XBIO, evaluating the profitability, health, valuation and growth aspects
- XENETIC BIOSCIENCES INC (XBIO) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- XENETIC BIOSCIENCES INC (XBIO) Sales and EPS estimates to see what analysts future expectations are.
- XENETIC BIOSCIENCES INC (XBIO) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- XENETIC BIOSCIENCES INC (XBIO) Insider and Institutional Ownership to learn about the owners and their transactions.
- XENETIC BIOSCIENCES INC (XBIO) Stock Chart to make your own analysis
- XENETIC BIOSCIENCES INC (XBIO) Latest news and press-releases to stay up to date.
Does XENETIC BIOSCIENCES INC (XBIO) stock pay dividends?
XBIO does not pay a dividend.
When does XENETIC BIOSCIENCES INC (XBIO) report earnings?
XENETIC BIOSCIENCES INC (XBIO) will report earnings on 2025-08-11.
What is the Price/Earnings (PE) ratio of XENETIC BIOSCIENCES INC (XBIO)?
XENETIC BIOSCIENCES INC (XBIO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.57).
What is the Short Interest ratio of XENETIC BIOSCIENCES INC (XBIO) stock?
The outstanding short interest for XENETIC BIOSCIENCES INC (XBIO) is 0.55% of its float. Check the ownership tab for more information on the XBIO short interest.
XBIO Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to XBIO. When comparing the yearly performance of all stocks, XBIO is a bad performer in the overall market: 80.04% of all stocks are doing better.
XBIO Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XBIO. XBIO has a great financial health rating, but its profitability evaluates not so good.
XBIO Financial Highlights
Over the last trailing twelve months XBIO reported a non-GAAP Earnings per Share(EPS) of -2.57. The EPS increased by 6.55% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -57.38% | ||
| ROE | -65.93% | ||
| Debt/Equity | 0 |
XBIO Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to XBIO. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of -28.59% and a revenue growth 27.27% for XBIO